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ABSTRACT
Background. Compared with chemotherapy, significant im-
provement in survival outcomes with the programmed death
receptor-1 (PD-1) inhibitors nivolumab and pembrolizumab and
the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab
has been shown in several types of advanced solid tumors.We
conducted a systematic review and meta-analysis to compare
safety and tolerability between PD-1/PD-L1 inhibitors and
chemotherapy.
Methods. PubMed and American Society of Clinical Oncology
(ASCO) databases were searched 1966 to September 2016. Eli-
gible studies included randomized controlled trials (RCTs) com-
paring single-agent U.S. Food and Drug Administration–
approved PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab,
or atezolizumab) with chemotherapy in cancer patients report-
ing any all-grade (1–4) or high-grade (3–4) adverse events (AEs),
all- or high-grade treatment-related symptoms, hematologic
toxicities and immune-related AEs, treatment discontinuation
due to toxicities, or treatment-related deaths. The summary
incidence, relative risk, and 95% confidence intervals were
calculated.
Results. A total of 3,450 patients from 7 RCTs were included in
the meta-analysis: 4 nivolumab, 2 pembrolizumab, and 1 ate-
zolizumab trials. The underlying malignancies included were
non-small cell lung cancer (4 trials) and melanoma (3 trials).
Compared with chemotherapy, the PD-1/PD-L1 inhibitors had
a significantly lower risk of all- and high-grade fatigue, sensory
neuropathy, diarrhea and hematologic toxicities, all-grade ano-
rexia, nausea, and constipation, any all- and high-grade AEs,
and treatment discontinuation. There was an increased risk of
all-grade rash, pruritus, colitis, aminotransferase elevations,
hypothyroidism, and hyperthyroidism, and all- and high-grade
pneumonitis with PD1/PD-L1 inhibitors.
Conclusion. PD-1/PD-L1 inhibitors are overall better tolerated
than chemotherapy. Our results provide further evidence sup-
porting the favorable risk/benefit ratio for PD-1/PD-L1 inhibi-
tors.The Oncologist 2017;22:470–479
Implications for Practice: We conducted a systematic review and meta-analysis to compare summary toxicity endpoints and
clinically relevant adverse events between programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors and
chemotherapy. PD1/PD-L1 inhibitors were associated with a lower risk of treatment-related symptoms (fatigue, anorexia, nausea,
diarrhea, constipation, and sensory neuropathy) but a higher risk of immune-related adverse events (AEs). Summary toxicity
endpoints favor PD1/PD-L1 inhibitors (any all- and high-grade AEs and treatment discontinuation). PD1/PD-L1 inhibitors are overall
better tolerated than chemotherapy. In addition to efficacy data from trials, our findings provide useful information for clinicians for
well-balanced discussions with their patients on the risks and benefits of treatment options for advanced cancer.
INTRODUCTION
The development of immune checkpoint inhibitors (ICIs) rep-
resents a major breakthrough in cancer therapy. ICIs enhance
antitumor immune responses by releasing the “brakes” on
the immune system [1]. They are designed to block immuno-
suppressive receptors expressed on the surface of T lympho-
cytes such as cytotoxic T-lymphocyte–associated antigen 4,
programmed death receptor-1 (PD-1), and the programmed
death-ligand 1 (PD-L1) expressed on tumor cells and tumor-
infiltrating immune cells [2]. ICIs targeting the PD-1/PD-L1
pathway have shown especially significant improvement in
progression-free survival and overall survival (OS) compared
with standard care in different advanced solid tumors [3–9].
Their superior efficacy led to U.S. Food and Drug Administra-
tion (FDA) approval of PD-1 inhibitors, nivolumab, and pem-
brolizumab for the treatment of unresectable or metastatic
melanoma and advanced non-small cell lung cancer (NSCLC)
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in the second-line setting [10, 11]. Nivolumab is also
approved for patients with metastatic renal cell carcinoma
following prior treatment with an anti-angiogenic therapy
[10]. Recently, the FDA approved the PD-L1 inhibitor atezoli-
zumab for the treatment of locally advanced or metastatic
urothelial carcinoma after prior platinum-based chemother-
apy [12]. Based on the remarkable durable responses in
single-arm trials, the FDA approved nivolumab for relapsed
or refractory Hodgkin’s lymphoma and pembrolizumab for
recurrent or metastatic head and neck squamous cell carci-
noma [10, 11]. The indications for these agents are expected
to continue expanding as they are studied in different treat-
ment settings, including first-line therapy for advanced dis-
ease and a wide variety of other malignancies [13].
Treatment decision-making for patients with advanced
cancer is a major challenge for oncologists. The goals of ther-
apy are often palliative: prolongation of survival, control of
symptoms, and maintenance or improvement of quality of
life. In order to attain these goals, it is essential to have a bal-
anced discussion of treatment options that focuses on the
benefits and risks of each treatment, taking into account
patient preferences and values. Currently, both novel immu-
notherapy agents and traditional cytotoxic chemotherapy are
approved treatment options for advanced cancer. In addition
to efficacy data derived from trials of impact on survival out-
comes, a comprehensive understanding of the toxicity profile
of immunotherapy compared chemotherapy is needed for
informed treatment decisions. Inhibition of the immune
checkpoints can lead to immune dysregulation that clinically
manifests with symptoms similar to autoimmune disease.
These side effects are termed immune-related adverse
events (AEs) and include dermatologic, gastrointestinal,
hepatic, endocrine, and pulmonary events [14]. In addition to
these unique AEs, classical chemotherapy toxicities, such as
fatigue, anorexia, nausea, and diarrhea, have also been seen
in patients treated with the PD-1/PD-L1 inhibitors [3–9].
These treatment-related symptoms are important, as they
affect patients’ quality of life [15, 16]. However, to date, there
has been no systematic comparison of tolerability between
PD-1/PD-L1 inhibitors and chemotherapy. We conducted a
systematic review and meta-analysis of randomized con-
trolled trials (RCTs) to compare summary toxicity endpoints
and clinically relevant AEs between PD-1/PD-L1 inhibitors
and chemotherapy.
MATERIALS AND METHODS
Data Source
This analysis was performed in accordance with the preferred
reporting items for systematic reviews and meta-analyses state-
ment [17]. Two authors (TFN and SSS) conducted independent
reviews of PubMed from January 1966 to September 30, 2016.
Search terms included ‘‘nivolumab,” ‘‘pembrolizumab,” and
“atezolizumab.” The search was limited to clinical trials. We also
searched abstracts and virtual meeting presentations utilizing
the same search terms from the American Society of Clinical
Oncology (ASCO) conferences held through September 2016 to
identify relevant studies. Independent searches of the Web of
Science, Embase, and Cochrane electronic databases were also
performed. In instances of duplicate publications, only the most
complete, recent, and up-to-date report of the study was
included.
Study Selection
Clinical trials that met the following criteria were included: (a)
phase II and III trials in patients with cancer; (b) random assign-
ment of participants to treatment with single-agent PD-1/
PD-L1 inhibitor or chemotherapy; and (c) reporting of events or
event rate and sample size for any all-grade (1–4) or high-grade
(3–4) AEs, individual all- or high-grade AEs, treatment discontin-
uation for AEs, or treatment-related deaths. For the individual
AEs, we included immune-related AEs (rash, pruritus, colitis,
hypothyroidism, hyperthyroidism, hypophysitis, hepatitis, and
pneumonitis), hematologic toxicities (neutropenia, anemia, and
thrombocytopenia), and the core set of 12 clinically relevant
symptoms recommended for assessment in clinical trials by the
National Cancer Institute’s Symptom Management and Health-
Related Quality of Life Steering Committee [18]. These 12 symp-
toms are fatigue, insomnia, pain, anorexia, dyspnea, cognitive
problems, anxiety, nausea, depression, sensory neuropathy,
constipation, and diarrhea. Reviewers (TFN and SSS) independ-
ently screened reports that included the key terms by their
titles and abstracts for relevance. Then, full texts of relevant
articles were retrieved to assess eligibility. The references of rel-
evant reports were also reviewed manually to identify addi-
tional studies.
Data Extraction
Two investigators (TFN and SSS) independently performed data
extraction. Any discrepancies between reviewers were resolved
by consensus. The following information was recorded for each
study: first author’s name, year of publication, trial phase, mask-
ing, underlying malignancy, treatment arms, number of patients
available for analysis, age, follow-up duration, Common Termi-
nology Criteria for AEs (CTCAE), any all- or high-grade AEs, indi-
vidual all- or high-grade AEs (fatigue, insomnia, pain, anorexia,
dyspnea, cognitive problems, anxiety, nausea, depression, sen-
sory neuropathy, constipation, diarrhea, neutropenia, thrombo-
cytopenia, anemia, rash, pruritus, colitis, hypothyroidism,
hyperthyroidism, hypophysitis, alanine aminotransferase (ALT)/
aspartate aminotransferase (AST) elevations, and pneumonitis),
treatment discontinuation for AEs, and treatment-related
deaths. AEs were recorded according to the CTCAE. The quality
of trials was rated using the five-point Jadad scale, which is
based on the reporting of randomization method, blinding
method, withdrawals, and dropouts [19].
Statistical Analysis
The primary objective of this study was to compare toxicity
between PD-1/PD-L1 inhibitors and chemotherapy. The relative
risk (RR), corresponding 95% confidence intervals (CIs), and
incidence of toxicity outcomes were calculated. We calculated
the RRs and CIs with data extracted from RCTs and assessed
the incidence of toxicity events in patients assigned to PD-1/
PD-L1 inhibitors compared with chemotherapy in the same
trial. To calculate the 95% CIs, the variance of the log-
transformed study-specific RR was derived using the delta
method. For studies reporting zero AEs in any arm, we applied
a classic half-integer continuity correction to calculate the RR
and variance. For the calculation of RRs, we used random- or
fixed-effects models depending on the heterogeneity of
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included studies. Statistical heterogeneity in results between
studies included in the meta-analysis was examined using
Cochrane’s Q statistic, and inconsistency was quantified with I2
statistic (100%3 (Q2 df)/Q) [20]. The assumption of homoge-
neity was considered invalid for p values less than .10. Sum-
mary RRs were calculated using random- or fixed-effects
models depending on the heterogeneity of included studies.
When substantial heterogeneity was not observed, the pooled
estimate calculated based on the fixed-effects model was
reported by using the inverse variance method.When substan-
tial heterogeneity was observed, the pooled estimate calcu-
lated based on the random-effects model was reported by
using the DerSimonian and Laird method, which considers both
within-study and between-study variations [21]. For the calcu-
lation of incidence, the proportion of patients with adverse out-
comes and 95% CIs was derived from each trial. We used a
random-effects model to produce a pooled overall estimate for
incidence of adverse outcomes. We evaluated publication bias
using funnel plots and the Begg and Egger tests [22, 23]. A two-
tailed p value of less than .05 was considered statistically signifi-
cant. Statistical analyses were performed using the comprehen-
sive meta-analysis program (Version 2, Biostat, Englewood, NJ,
USA).
RESULTS
Search Results and Patient Characteristics
Our search strategy yielded 166 potentially relevant records
in the PubMed and ASCO databases, of which 159 publica-
tions were excluded. Our selection process and reasons for
study exclusion are shown in Figure 1. A total of four phase
III, one phase II/III, and two phase II randomized clinical trials
were considered eligible for the meta-analysis. A total of
3,450 patients (PD-1/PD-L1 inhibitors: 2,090; chemotherapy:
1,360) were included in the analysis from four nivolumab tri-
als, two pembrolizumab trials, and one atezolizumab trial.
The underlying malignancies were NSCLC (4 trials) and mela-
noma (3 trials). The baseline characteristics in each trial are
presented in Table 1.
Comparison of Toxicity Profiles
Summary Toxicity Endpoints
The incidence of any all-grade (67.6% versus 82.9%) or high-
grade (11.4% versus 35.7%) AEs was lower in PD-1/PD-L1 inhib-
itors compared with chemotherapy (Table 2). PD-1/PD-L1 inhib-
itors also had significantly lower risk of any all-grade (RR 0.82;
p< .001) and high-grade AEs (RR 0.32; p< .001; Fig. 2).
Patients treated with PD-1/PD-L1 inhibitors stopped therapy
for toxicity less frequently than those treated with chemother-
apy (4.5% versus 11.1%); the RR of treatment discontinuation
due to AEs was 0.44 (p< .001). Deaths attributed to study
treatment occurred in 7 patients in the PD-1/PD-L1 inhibitor
group and 11 patients in the chemotherapy group. There was
no significant difference in the incidence of treatment-related
deaths between the two groups. The random-effects model
was used for the RR analysis of any all- and high-grade AEs
because there was significant heterogeneity among the studies.
The test for heterogeneity was not significant for treatment dis-
continuation and treatment-related deaths. Therefore, the
Figure 1. Flow diagram: selection process for the studies.
Abbreviations: ASCO, American Society of Clinical Oncology; PD-1, programmed death receptor-1; PD-L1, programmed death-ligand 1.
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fixed-effects model was used for these RR analyses. The RR and
incidence for each AE are summarized in Table 2.
Clinically Relevant Treatment-Related Symptoms
Of the core set of 12 clinically relevant symptoms, fatigue, ano-
rexia, nausea, constipation, diarrhea, and pain were reported in
all 7 trials. The overall incidence of all-grade or high-grade pain
in the trials could not be obtained because only incidences of
pain in specific sites were reported. Data for sensory neuropa-
thy were available from six trials, and data for insomnia and
dyspnea were available from three trials. Only one trial
reported anxiety, and no trial reported cognitive problems or
depression. Based on the availability of data, summary inci-
dence and RR were calculated for the following eight symp-
toms: fatigue, anorexia, nausea, constipation, diarrhea, sensory
neuropathy, insomnia, and dyspnea. PD-1/PD-L1 inhibitors
were associated with a significantly lower risk for six of the
eight evaluated all-grade AEs when compared with chemother-
apy (Table 3): fatigue (19.1% versus 27.7%; RR 0.69), anorexia
(10.2% versus 15.8%; RR 0.65), nausea (11.5% versus 28.4%;
RR 0.41), constipation (5.2% versus 9.9%; RR 0.57), diarrhea
(10.2% versus 17.3%; RR 0.61), and sensory neuropathy (1.2%
versus 8.6%; RR 0.16). The risk of three high-grade AEs was sig-
nificantly lower in the PD-1/PD-L1 inhibitor group compared
with the chemotherapy group: fatigue (0.7% versus 4.0%; RR
0.19), sensory neuropathy (0.3% versus 1.1%; RR 0.20), and
diarrhea (0.6% versus 1.9%; RR 0.30). We found no statistically
significant differences between the groups for all-grade insom-
nia, dyspnea, high-grade anorexia, nausea, constipation, insom-
nia, or dyspnea.
Hematologic Toxicities
Patients treated with PD-1/PD-L1 inhibitors had a significantly
lower risk of all-grade neutropenia (0.5% versus 16.1%; RR
0.04), anemia (3.4% versus 16.2%; RR 0.22), and thrombocyto-
penia (0.6% versus 7.0%; RR 0.11). A risk of high-grade neutro-
penia, anemia, and thrombocytopenia was also statistically
significant lower in the PD-1/PD-L1 inhibitor group compared
with the chemotherapy group (Table 3).
Table 1. Characteristics of the studies included in the meta-analysis
Author, year
[reference] Phase Masking Histology Treatment arms
No. of
patients
foranalysis
Age in
years
(median)
Follow-up
(months)
CTCAE
version
Jadad
score
Robert,
2014 [3]
III Double-blind Melanoma Nivolumab 3 mg/kg
q2 weeks1 Placebo
210 64 (18–86) 16.7 4 5
Dacarbazine
1,000 mg/m2
q3 weeks1 Placebo
208 66 (26–87)
Weber,
2014 [4]
III Open-label Melanoma Nivolumab 3 mg/kg
q2 weeks
268 59 (23–88) 8.4 4 3
Investigator-choice
chemotherapya
102 62 (29–85)
Brahmer,
2015 [5]
III Open-Label Squamous
NSCLC
Nivolumab 3 mg/kg
q2 weeks
135 62 (39–85) 11 4 3
Docetaxel 75 mg/m2
q3 weeks
137 64 (42–84)
Ribas,
2015 [6]
II Open-Label Melanoma Pembrolizumab
2 mg/kg q3 weeks
180 62 (15–87) 10 4 3
Pembrolizumab
10 mg/kg q3 weeks
181 60 (27–89)
Investigator-choice
chemotherapyb
179 63 (27–87)
Borghaei,
2015 [7]
III Open-Label Nonsquamous
NSCLC
Nivolumab 3 mg/kg
q2 weeks
292 61 (37–84) 17.2 4 3
Docetaxel 75 mg/m2
q3 weeks
290 64 (21–85)
Herbst,
2016 [8]
II/III Open-Label NSCLC Pembrolizumab
2 mg/kg q3 weeks
339 63 (56–69) 13.1 4 3
Pembrolizumab
10 mg/kg q3 weeks
343 63 (56–69)
Docetaxel 75 mg/m2
q3 weeks
309 62 (56–69)
Fehrenbacher,
2016 [9]
II Open-Label NSCLC Atezolizumab
1,200 mg q3 weeks
142 62 (42–82) 14.8 4 3
Docetaxel 75 mg/m2
q3 weeks
135 62 (36–84)
aDacarbazine, or paclitaxel plus carboplatin.
bPaclitaxel plus carboplatin, paclitaxel, carboplatin, dacarbazine, or oral temozolomide.
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; NSCLC, non-small cell lung cancer; q, every.
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Immune-Related AEs
PD-1/PD-L1 inhibitors were associated with a significantly higher
risk for all-grade immune-related AEs, including dermatologic
(rash and pruritus), gastrointestinal (colitis), hepatic (AST/ALT
elevations), endocrine (hypothyroidism and hyperthyroidism),
and pulmonary (pneumonitis) events. There was also a small
but statistically significant increase in the risk of high-grade
pneumonitis with PD-1/PD-L1 inhibitors compared with chemo-
therapy (1.3% versus 0.6%; RR 3.21).
Exploratory Subgroup Analysis
To investigate possible reasons for heterogeneity, we did sub-
group analyses with regard to the RRs by type of chemotherapy
regimen (docetaxel versus others) and type of tumor (NSCLC
versus melanoma). As all NSCLC trials used docetaxel and all
melanoma trials used non-docetaxel regimens in the chemo-
therapy arms, the same results were obtained from the sub-
group analyses according to chemotherapy type and tumor
type. Using Q statistics, there were significant differences in the
risk of all-grade fatigue, anorexia, and diarrhea, all- and high-
grade nausea, and any all-grade AEs between these subgroups.
Otherwise, a similar toxicity profile in comparison with PD-1/
PD-L1 inhibitors was observed in both chemotherapy sub-
groups. The exploratory subgroup analyses are summarized in
Table 4.
Study Quality and Publication Bias
Six trials were open label, whereas one trial was double blind
placebo controlled. The Jadad score ranged from 3 to 5 with a
mean was 3.3, indicating that overall study quality was fair
Figure 2. Forest plots of relative risk of any all- and high-grade AEs associated with PD-1/PD-L1 inhibitors versus chemotherapy.
Abbreviations: AE, adverse event; CI, confidence interval; PD-1, programmed death receptor-1; PD-L1, programmed death-ligand 1.
Table 2. Incidence and RR of summary toxicity endpoints, including 95% CI and number of trials in each analysis
Summary AE endpoints
No. of
trials
PD-1/PD-L1 inhibitor
incidence % (95% CI)
Chemotherapy
incidence % (95% CI) RR (95% CI) p value
Any all-grade AEs 7 67.6 (64.2–70.8) 82.9 (78.9–86.2) 0.82 (0.76–0.88) <.001
Any high-grade AEs 7 11.4 (9.9–13.1) 35.7 (26.0–46.8) 0.32 (0.22–0.45) <.001
Treatment discontinuation 7 4.5 (3.5–5.7) 11.1 (8.5–14.3) 0.44 (0.33–0.57) <.001
Treatment-related deaths 3 0.6 (0.3–1.1) 1.4 (0.7–2.5) 0.42 (0.16–1.13) .09
Abbreviations: AE, adverse event; CI, confidence interval; PD-1, programmed death receptor-1; PD-L1, programmed death-ligand 1; RR, relative
risk.
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(Table 1). For RR of all-grade constipation and pneumonitis and
high-grade colitis, the Egger test suggested some evidence of
publication bias. However, the Begg tests showed no evidence
of bias (p> .05). This difference in the results obtained from
the two methods may be due to a greater statistical power of
the Egger test [24].
DISCUSSION
We compared the tolerability of ICIs targeting PD1/PD-L1 path-
way and standard-of-care chemotherapy in patients with
advanced cancer by performing a meta-analysis of RCTs. PD1/
PD-L1 inhibitors were associated with a lower risk of
treatment-related symptoms (fatigue, anorexia, nausea, diar-
rhea, constipation, and sensory neuropathy) and hematologic
toxicities. However, there was an increased risk of immune-
related AEs, including dermatologic, gastrointestinal, hepatic,
endocrine, and pulmonary events in patients treated with PD1/
PD-L1 inhibitors. Most of these events were low-grade, but
high-grade events were described, especially pneumonitis [25].
Clinicians need to be aware of the risk of these unique toxicities
and manage them appropriately according to the algorithm for
diagnosis and treatment adapted from guidelines used across
anti-PD-1/PD-L1 trials [26].
PD1/PD-L1 inhibitors were associated with a lower
risk of treatment-related symptoms (fatigue, anorexia,
nausea, diarrhea, constipation, and sensory neuropa-
thy) and hematologic toxicities. However, there was
an increased risk of immune-related AEs, including
dermatologic, gastrointestinal, hepatic, endocrine, and
pulmonary events in patients treated with PD1/PD-L1
inhibitors.
Our analysis of summary toxicity endpoints revealed a
lower risk of any all- and high-grade AEs and treatment discon-
tinuation in the PD1/PD-L1 inhibitor group. Importantly, abso-
lute difference in risk and RR was more substantial for any
high-grade AEs (11.4% versus 35.7%, RR 0.32) than for any all-
grade AEs (67.6% versus 82.9%, RR 0.82), and this is related to
the lower incidence of treatment discontinuation due to toxic-
ities (4.5% versus 11.1%, RR 0.44) in the PD1/PD-L1 inhibitor
group compared with the chemotherapy group. Overall, PD1/
PD-L1 inhibitors in these clinical trials were better tolerated
than chemotherapy.
CTCAE has been the standard method to evaluate toxicities
and has been widely used in cancer clinical trials for more than
2 decades. AEs are graded based on the clinician’s assessment
of toxicity [27]. However, studies have shown that clinician-
measured CTCAEs underestimated the incidence and/or sever-
ity of symptoms actually experienced by cancer patients [28].
Basch et al. longitudinally collected clinician, as compared with
patient, adverse symptom reports from 163 patients with lung
cancer receiving chemotherapy [29]. This study found that clini-
cian CTCAE assessments are better in predicting unfavorable
clinical events, such as death and emergency room admissions,
but that patients generally reported symptoms earlier and
more frequently that better reflected their daily health status.
The authors concluded that clinician and patient-reported
measures are complementary, each providing clinically mean-
ingful information. Based on these findings, patient-reported
outcomes (PRO) have been added to recent cancer clinical tri-
als. The recent clinical trials of PD1/PD-L1 inhibitors have incor-
porated the European Organization for the Research and
Treatment of Cancer (EORTC) Quality of Life Questionnaire C30
(QLQ-C30) and other PRO measures [3–9]. Of the clinical trials
included in our meta-analysis, two trials reported the results of
PROs. In the clinical trial of pembrolizumab versus chemother-
apy in advanced melanoma, EORTC QLQ-C30 data were
collected at baseline and at week 12 [6]. A significant deteriora-
tion in the global health status quality-of-life score (10 points or
more) was experienced by 7% to 12% fewer patients in the
pembrolizumab group compared with the chemotherapy
group. Patients treated with pembrolizumab had consistently
smaller decrements in the symptoms scales for fatigue, nausea,
anorexia, diarrhea, and constipation. Recently, Long et al.
reported PRO outcomes in the trial of nivolumab versus dacar-
bazine in patients with advanced melanoma [30]. The EORTC
QLQ-C30 was evaluated at baseline and every 6 weeks while on
treatment. Compared with dacarbazine, patients treated with
nivolumab maintained better global health longer (hazard ratio
[HR] 0.65; 95% CI 0.46–0.92) and better physical function (HR
0.60; 95% CI 0.42–0.87). These results suggested that PD1
inhibitors were better tolerated than chemotherapy based on
the patients’ perspective and were consistent with the findings
in our meta-analysis.
Based on the efficacy and favorable toxicity profile of ICIs,
their utility in the treatment of older patients and patients with
impaired functional status is of great interest. Our group per-
formed a meta-analysis of nine RCTs comprising 5,265 patients
to compare the efficacy of ICIs between younger and older
patients. We showed that ICIs significantly improved OS com-
pared with controls in both younger (HR 0.75; 95% CI 0.68–
0.82) and older (HR 0.73; 95% CI 0.62–0.87) patients, using an
older age cut-point of 65–70 years [31].
Recently, the FDA performed a pooled analysis of 1,030
patients from four registration trials of nivolumab for advanced
cancer [32]. Toxicity was reported separately for three age
groups (<65 years, 616 patients; 65 to<70 years, 414 patients;
and 70 years, 212 patients). The incidence of any grade 1–2
and grade 3–4 toxicities were, respectively, <65 years: 39%
and 44%; 65 to <70 years: 35% and 45%; 70 years: 37% and
46%. The frequency and severity of AEs were similar across the
age groups in this retrospective analysis. To assess the efficacy
and safety in more general patient population, a phase IV study
of nivolumab was conducted in patients with advanced NSCLC
[33]. This trial included 65 patients with performance status
(PS) 2. Notably, there was no obvious difference in efficacy and
toxicity outcomes between PS 2 patients and PS 0–1 patients.
As PS is a crude measure of patients’ functional status, further
studies of PD1/PD-L1 inhibitors in older and/or frail patients
using geriatric assessments are warranted to evaluate efficacy
and safety as well as health-related quality-of-life outcomes.
Our study has some limitations. First, the results described
here are affected by the limitations of individual clinical trials
that were selected for this meta-analysis. As five of six included
trials used an open-label design, these trials were liable to
ascertainment bias. Second, this is a meta-analysis at the study
level; therefore, variables at the patient level were not included
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in the analysis. Thus, we could not establish risk factors associ-
ated with the development of toxicities. Third, the patients in
studies selected for our meta-analysis were a select group of
patients with good PS who were recruited into clinical trials
conducted at academic centers. The actual incidence of toxic-
ities in patients with organ dysfunction and/or an impaired
functional status is likely to be higher in clinical practice. How-
ever, the patient selection into the trails in our study is unlikely
to introduce bias into the RR analysis of the toxicities. Finally,
significant heterogeneity was observed in the included studies
for some of the planned RR analyses. We minimized heteroge-
neity influence by using the random-effects model and also
performed exploratory subgroup analyses based on type of
chemotherapy regimen (docetaxel versus others) and type of
tumor (NSCLC versus melanoma). As there were differences in
the risk of some individual AEs between the subgroups, the
observed heterogeneity may be partially explained by the dif-
ferences in these factors.
CONCLUSION
Our analysis suggests that PD1/PD-L1 inhibitors are better tol-
erated than standard-of-care chemotherapy in patients
with advanced cancer. In addition to the efficacy results
from trials, our findings provide useful information for
clinicians for well-balanced discussions with their patients
on the risks and benefits of treatment options for advanced
cancer. Further research on this promising immunothera-
peutic approach is needed to assess efficacy, toxicity, and
PROs in older patients and patients with poorer health sta-
tus who are generally not included in the clinical trials.
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Implications for Practice:
The potential adverse events of immune checkpoint inhibitors differ from conventional chemotherapy and can require a multidisci-
plinary approach. Continued education is important for all physicians to ensure optimal care for patients.
Nishijima, Shachar, Nyrop et al. 479
www.TheOncologist.com Oc AlphaMed Press 2017
